Medical management of recurrent endometrioma with long-term norethindrone acetate.

Abstract

PURPOSE:

Evaluate the efficacy of norethindrone acetate in the resolution of symptoms and regression of recurrent endometrioma.

PATIENTS AND METHODS:

Retrospective chart review at SUNY Downstate Medical Center of patients with a history of surgical excision of endometrioma (with histological confirmation) and recurrent endometrioma (demonstrated by strict sonographic criterion of endometrioma) who were willing to undergo follow-up. Patients were prescribed norethindrone acetate to be taken daily with follow-up sonograms until cysts regressed. Statistical analysis included Student's t-test and a simple linear regression model to assess cyst regression over time during treatment.

RESULTS:

Degree of pain was significantly lower on treatment when compared to baseline (P < 0.00001). Cyst size was significantly smaller in as little as 3 months (P < 0.0001). Average rate of regression with continuous treatment was 0.025 ± 0.015 cm/day. Total mean ± standard deviation regression time is 10.28 ± 8.25 months.

CONCLUSION:

Norethindrone acetate was effective in eradicating symptoms and producing complete regression of recurrent endometriomas. It should be considered for patients who are likely to adhere to a prolonged treatment regimen and comply with recommendations for surveillance with serial sonograms.

• Authors: Ozgul Muneyyirci-Delale, Jenny Anopa, Cassandra Charles, Deepali Mathur, Rudolph Parris, Jed B Cutler, Ghadir Salame, Ovadia Abulafia
• Journal: International journal of women's health (Int J Womens Health) Vol. 4 Pg. 149-54 ( 2012) ISSN: 1179-1411 [Electronic] New Zealand
• PMID: 22505834 (Publication Type: Journal Article)